VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
GDRXGoodRx Holdings, Inc.
$2.66$922M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist

GDRX logoGoodRx Holdings, Inc.(GDRX)Earnings, Financials & Key Ratios

GDRX•NASDAQ
31.2× P/E·Price updated Jun 19, 2026
SectorHealthcareIndustryHealthcare ITSub-IndustryPatient Engagement, Intake and Payments
AboutGoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including subscriptions, pharma manufacturer solutions, and telehealth services. It serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was incorporated in 2015 and is headquartered in Santa Monica, California.Show more
  • Revenue$797M+0.6%
  • EBITDA$173M+27.6%
  • Net Income$30M+85.7%
  • EPS (Diluted)0.09+104.1%
  • Gross Margin92.77%-1.2%
  • EBITDA Margin21.67%+26.8%
  • Operating Margin10.98%+32.1%
  • Net Margin3.82%+84.7%
  • ROE4.54%+105.9%

GDRX Key Insights

GoodRx Holdings, Inc. (GDRX) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓FCF machine: 20.6% free cash flow margin
  • ✓High quality earnings: Operating CF exceeds net income
  • ✓Share count reduced 9.0% through buybacks

✗Weaknesses

  • ✗Weak 3Y average ROE of 1.9%
  • ✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Get notified when GDRX posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

GDRX Price & Volume

GoodRx Holdings, Inc. (GDRX) stock price & volume — 10-year historical chart

Loading chart...

GDRX Growth Metrics

GoodRx Holdings, Inc. (GDRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years7.67%
3 Years1.3%
TTM-1.19%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-19.73%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-16.63%

Return on Capital

10 Years6.15%
5 Years2.25%
3 Years3.41%
Last Year7.22%

GDRX Recent Earnings

GoodRx Holdings, Inc. (GDRX) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 1/12 qtrs (8%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 6, 2026
Metric
Actual
Est
EPS
$0.07+0.0%
$0.07
Rev
$194M+4.6%
$185M
Q1 2026
Feb 25, 2026
Metric
Actual
Est
EPS
$0.09+0.0%
$0.09
Rev
$195M+0.8%
$193M
Q4 2025
Nov 4, 2025
Metric
Actual
Est
EPS
$0.08-11.1%
$0.09
Rev
$196M+1.4%
$193M
Q3 2025
Aug 6, 2025
Metric
Actual
Est
EPS
$0.09-10.0%
$0.10
Rev
$203M-1.1%
$205M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 6, 2026
$0.07vs $0.07+0.0%
$194Mvs $185M+4.6%
Q1 2026Feb 25, 2026
$0.09vs $0.09+0.0%
$195Mvs $193M+0.8%
Q4 2025Nov 4, 2025
$0.08vs $0.09-11.1%
$196Mvs $193M+1.4%
Q3 2025Aug 6, 2025
$0.09vs $0.10-10.0%
$203Mvs $205M-1.1%
Based on last 12 quarters of dataView full earnings history →

GDRX Peer Comparison

GoodRx Holdings, Inc. (GDRX) competitors in Patient Engagement, Intake and Payments — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
Institutional Holdings
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
HIMS logoHIMSHims & Hers Health, Inc.Direct Competitor7.79B35.4769.5559%-0.56%-2.48%2.34
TDOC logoTDOCTeladoc Health, Inc.Direct Competitor1.46B8.07-7.08-1.54%-6.81%-12.37%0.75
OPRX logoOPRXOptimizeRx CorporationDirect Competitor93.45M4.9818.4418.78%6.37%5.47%0.20
PHVS logoPHVSPharvaris N.V.Direct Competitor2.15B32.80-9.60-67.38%0.00
DOCS logoDOCSDoximity, Inc.Product Competitor3.83B20.4620.8813.05%30.4%19.36%0.01
AMWL logoAMWLAmerican Well CorporationProduct Competitor140.85M8.43-1.41-1.98%-48.16%-33.48%0.02
PGNY logoPGNYProgyny, Inc.Product Competitor2.04B26.0840.1210.4%5.23%13.34%0.05
CVS logoCVSCVS Health CorporationSupply Chain125.45B98.3270.737.85%0.72%3.86%1.24

Compare GDRX vs Peers

GoodRx Holdings, Inc. (GDRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs HIMS

Most directly comparable listed peer for GDRX.

Scale Benchmark

vs UNH

Larger-name benchmark to compare GDRX against a more recognizable public peer.

Peer Set

Compare Top 5

vs HIMS, TDOC, OPRX, PHVS

GDRX Income Statement

GoodRx Holdings, Inc. (GDRX) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
MetricDec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Sales/Revenue
249.52M388.22M550.7M745.42M766.55M750.26M792.32M796.85M787.89M
Revenue Growth %
-55.59%41.85%35.36%2.83%-2.13%5.61%0.57%-1.19%
Cost of Goods Sold
6.04M14.02M29.59M46.72M65.08M66.92M48.22M57.6M84.12M
COGS % of Revenue
2.42%3.61%5.37%6.27%8.49%8.92%6.09%7.23%-
Gross Profit
243.49M▲ 0%
374.21M▲ 53.7%
521.11M▲ 39.3%
698.71M▲ 34.1%
701.48M▲ 0.4%
683.34M▼ 2.6%
744.11M▲ 8.9%
739.26M▼ 0.7%
703.77M▲ 0%
Gross Margin %
97.58%96.39%94.63%93.73%91.51%91.08%93.91%92.77%89.32%
Gross Profit Growth %
-53.69%39.26%34.08%0.4%-2.59%8.89%-0.65%-
Operating Expenses
166.24M234.53M796.83M685.3M699.74M710.35M678.26M651.76M624.75M
OpEx % of Revenue
66.62%60.41%144.69%91.93%91.28%94.68%85.6%81.79%-
Selling, General & Admin
112.54M191.66M716.59M524.9M502.42M466.84M484.98M445.52M439.22M
SG&A % of Revenue
45.1%49.37%130.12%70.42%65.54%62.22%61.21%55.91%-
Research & Development
43.89M29.3M61.82M125.86M143.14M135.84M123.75M121.03M120.06M
R&D % of Revenue
17.59%7.55%11.22%16.88%18.67%18.11%15.62%15.19%-
Other Operating Expenses
-7K13.57M18.43M34.54M54.18M107.67M69.54M85.22M2.1M
Operating Income
77.25M▲ 0%
139.68M▲ 80.8%
-275.72M▼ 297.4%
13.41M▲ 104.9%
1.74M▼ 87.0%
-27.01M▼ 1653.9%
65.85M▲ 343.8%
87.49M▲ 32.9%
79.02M▲ 0%
Operating Margin %
30.96%35.98%-50.07%1.8%0.23%-3.6%8.31%10.98%10.03%
Operating Income Growth %
-80.81%-297.4%104.86%-87.04%-1653.91%343.81%32.87%-
EBITDA
87.06M153.25M-257.29M47.95M55.91M80.66M135.38M172.71M165.12M
EBITDA Margin %
34.89%39.47%-46.72%6.43%7.29%10.75%17.09%21.67%20.96%
EBITDA Growth %
-76.03%-267.89%118.63%16.62%44.26%67.84%27.57%5.61%
D&A (Non-Cash Add-back)
9.81M13.57M18.43M34.54M54.18M107.67M69.54M85.22M86.1M
EBIT
74.54M132.55M-275.54M13.46M11.01M1.16M84.38M99.14M69.52M
Net Interest Income
-22.04M-48.85M-27.75M-23.58M-24.97M-24.56M-29.65M-31.67M-24.96M
Interest Income
154K715K160K59K9.27M32.17M23.27M10.93M6.09M
Interest Expense
22.19M49.57M27.91M23.64M34.24M56.73M52.92M42.6M19.89M
Other Income/Expense
-24.9M-56.7M-27.73M-23.58M-24.97M-28.57M-34.39M-30.95M-33.51M
Pretax Income
52.35M▲ 0%
82.98M▲ 58.5%
-303.45M▼ 465.7%
-10.18M▲ 96.6%
-23.23M▼ 128.3%
-55.57M▼ 139.2%
31.46M▲ 156.6%
56.54M▲ 79.7%
45.51M▲ 0%
Pretax Margin %
20.98%21.37%-55.1%-1.37%-3.03%-7.41%3.97%7.1%5.78%
Income Tax
8.55M16.93M-9.83M15.08M9.6M-46.7M15.07M26.1M16.01M
Effective Tax Rate %
16.34%20.4%3.24%-148.15%-41.31%84.04%47.9%46.16%35.19%
Net Income
43.79M▲ 0%
66.05M▲ 50.8%
-293.62M▼ 544.6%
-25.25M▲ 91.4%
-32.83M▼ 30.0%
-8.87M▲ 73.0%
16.39M▲ 284.8%
30.44M▲ 85.7%
29.5M▲ 0%
Net Margin %
17.55%17.01%-53.32%-3.39%-4.28%-1.18%2.07%3.82%3.74%
Net Income Growth %
-50.82%-544.56%91.4%-29.99%72.99%284.82%85.72%-19.73%
Net Income (Continuing)
43.79M66.05M-293.62M-25.25M-32.83M-8.87M16.39M30.44M29.5M
Discontinued Operations
000000000
Minority Interest
000000000
EPS (Diluted)
0.12▲ 0%
0.12▲ 0.0%
-1.07▼ 991.7%
-0.06▲ 94.4%
-0.08▼ 33.3%
-0.02▲ 73.0%
0.04▲ 293.5%
0.09▲ 104.1%
0.09▲ 0%
EPS Growth %
-0%-991.67%94.39%-33.33%73%293.52%104.07%-16.63%
EPS (Basic)
0.120.12-1.07-0.06-0.08-0.020.040.09-
Diluted Shares Outstanding
362.6M362.6M274.7M409.98M412.86M410.31M392.17M356.97M341.42M
Basic Shares Outstanding
356.07M356.07M274.7M409.98M412.86M410.31M385.74M356.33M340.53M
Dividend Payout Ratio
3074.36%--------

GDRX Balance Sheet

GoodRx Holdings, Inc. (GDRX) balance sheet — assets, liabilities & shareholders' equity

MetricDec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Total Current Assets
73.07M86.58M1.09B1.09B919.69M872.79M659.25M643.1M1.27B
Cash & Short-Term Investments
34.6M26.05M971.59M941.11M757.16M672.3M448.35M261.82M235.71M
Cash Only
34.6M26.05M971.59M941.11M757.16M672.3M448.35M261.82M235.71M
Short-Term Investments
000000000
Accounts Receivable
33.36M55.52M97.29M126.41M121.67M160.04M160.83M235.75M232.72M
Days Sales Outstanding
48.852.264.4961.957.9377.8674.09107.98102.81
Inventory
000000000
Days Inventory Outstanding
---------
Other Current Assets
1.66M0021.31M35.1M15.48M50.08M145.54M798.04M
Total Non-Current Assets
241.72M300.21M408.22M518.8M684.95M716.01M728.81M760.96M754.78M
Property, Plant & Equipment
988K34.17M50.77M49.32M55.73M45.86M40.46M41.08M40.49M
Fixed Asset Turnover
252.55x11.36x10.85x15.11x13.76x16.36x19.58x19.40x19.22x
Goodwill
220.42M236.22M261.12M329.7M412.12M410.77M410.77M430.33M430.33M
Intangible Assets
18.27M26.45M56.72M133.78M189.94M156.34M176.88M64.08M61.17M
Long-Term Investments
0000015M15M00
Other Non-Current Assets
1.18M1.16M2.02M6.01M27.16M22.77M8.52M168.36M169.75M
Total Assets
314.79M▲ 0%
386.8M▲ 22.9%
1.49B▲ 286.4%
1.61B▲ 7.6%
1.6B▼ 0.2%
1.59B▼ 1.0%
1.39B▼ 12.6%
1.4B▲ 1.2%
2.02B▲ 0%
Asset Turnover
0.79x1.00x0.37x0.46x0.48x0.47x0.57x0.57x0.52x
Asset Growth %
-22.87%286.4%7.56%-0.19%-0.99%-12.63%1.15%44.42%
Total Current Liabilities
16.62M33.37M59.55M81.11M76.32M122.56M123.9M246M859.2M
Accounts Payable
7.2M7.85M10.29M17.5M17.7M36.27M14.14M19.41M14.53M
Days Payables Outstanding
435.46204.45126.95136.7499.27197.79107.02122.9795.53
Short-Term Debt
5.43M7.03M11.57M7.03M7.03M8.79M5M9.75M9.98M
Deferred Revenue (Current)
258K3.45M6.85M6.87M7.88M7.11M0012.36M
Other Current Liabilities
2.54M017.23M0033.82M69.41M216.84M834.7M
Current Ratio
4.40x2.59x18.24x13.42x12.05x7.12x5.32x2.61x1.47x
Quick Ratio
4.40x2.59x18.24x13.42x12.05x7.12x5.32x2.61x1.47x
Cash Conversion Cycle
--------7.28
Total Non-Current Liabilities
1.46B1.44B723.68M694.83M713.48M704.28M539.51M541.79M540.07M
Long-Term Debt
716.81M663.89M659.89M655.86M651.8M647.7M486.71M49.79M48.95M
Capital Lease Obligations
-737.01M37.13M33.47M33.59M54.13M48.4M46.04M0104M
Deferred Tax Liabilities
3.46M024.48M244K00000
Other Non-Current Liabilities
-733.68M739.98M5.85M5.14M7.56M8.18M6.75M492M491.11M
Total Liabilities
1.48B1.47B783.23M775.95M789.8M826.84M663.41M787.8M1.4B
Total Debt
722.24M710.99M704.92M702.33M717.02M711.07M543.39M59.54M58.93M
Net Debt
687.64M684.94M-266.67M-238.78M-40.14M38.77M95.04M-202.28M-176.78M
Debt / Equity
--0.99x0.84x0.88x0.93x0.75x0.10x0.09x
Debt / EBITDA
8.30x4.64x-14.65x12.82x8.82x4.01x0.34x0.36x
Net Debt / EBITDA
7.90x4.47x--4.98x-0.72x0.48x0.70x-1.17x-1.07x
Interest Coverage
3.36x2.67x-9.87x0.57x0.32x0.02x1.59x2.33x3.50x
Total Equity
-1.16B▲ 0%
-1.09B▲ 6.4%
711.36M▲ 165.4%
831.68M▲ 16.9%
814.83M▼ 2.0%
761.96M▼ 6.5%
724.66M▼ 4.9%
616.26M▼ 15.0%
621.99M▲ 0%
Equity Growth %
-6.44%165.41%16.91%-2.03%-6.49%-4.9%-14.96%-37.59%
Book Value per Share
-3.21-3.002.592.031.971.861.851.731.82
Total Shareholders' Equity
-1.16B-1.09B711.36M831.68M814.83M761.96M724.66M616.26M621.99M
Common Stock
451K460K39K40K40K40K38K34K34K
Retained Earnings
-1.16B-1.1B-1.39B-1.42B-1.45B-1.46B-1.44B-1.41B-1.41B
Treasury Stock
000000000
Accumulated OCI
-554K00000000
Minority Interest
000000000

GDRX Cash Flow Statement

GoodRx Holdings, Inc. (GDRX) cash flow — operating, investing & free cash flow history

MetricDec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Cash from Operations
45.25M83.29M131.34M178.78M146.78M138.29M183.89M167.9M170.33M
Operating CF Margin %
18.14%21.45%23.85%23.98%19.15%18.43%23.21%21.07%-
Operating CF Growth %
-84.05%57.7%36.12%-17.9%-5.78%32.97%-8.69%397.87%
Net Income
43.79M66.05M-293.62M-25.25M-32.83M-8.87M16.39M25.01M29.5M
Depreciation & Amortization
9.81M13.57M18.43M34.54M54.18M111.77M69.54M81.68M82.56M
Stock-Based Compensation
1.76M3.75M397.29M160.46M120.23M104.82M99.03M58.66M39.48M
Deferred Taxes
-2.43M-5.67M-10.91M12.85M-497K-65.56M-11.91M04.07M
Other Non-Cash Items
4.1M10.41M52.62M7.98M25.98M18.07M8.76M59M71.48M
Working Capital Changes
-11.77M-4.82M-32.46M-11.8M-20.29M-21.94M2.09M-56.44M-42.39M
Change in Receivables
-12.84M-14.52M-16.14M-43.95M1.38M-26.47M-2.33M-88.02M-70.81M
Change in Inventory
-2.55M00000000
Change in Payables
665K515K2.15M4.21M-874K17.46M-21.24M4.1M-1.13M
Cash from Investing
-3.46M-37.05M-91.62M-178.73M-210.5M-55.77M-70.35M-119.96M-89.73M
Capital Expenditures
-3.46M-1.43M-20.55M-4.57M-3.97M-1.04M0-2.28M-39.61M
CapEx % of Revenue
1.39%0.37%3.73%0.61%0.52%0.14%8.88%0.29%5.03%
Acquisitions
0-31.31M-55.79M-144.28M-155.28M00-30M0
Investments
---------
Other Investing
-2.65M-4.32M-15.27M-29.89M-51.25M-54.72M-70.35M-87.68M-50.12M
Cash from Financing
-24.73M-54.78M905.82M-30.53M-120.23M-167.4M-337.5M-234.47M-145.87M
Debt Issued (Net)
606.88M-57.23M-7.03M-7.03M-7.03M-5.27M-167M-3.75M-5M
Equity Issued (Net)
01.62M991.79M0-101.72M-103.97M-158.84M-206.94M-129.81M
Dividends Paid
-1.35B00000000
Share Repurchases
0000-101.72M-103.97M-158.84M-206.94M-129.04M
Other Financing
714.75M828K-78.95M-23.5M-11.48M-58.15M-11.64M-23.78M-11.06M
Net Change in Cash
17.06M▲ 0%
-8.55M▼ 150.1%
945.54M▲ 11159.0%
-30.48M▼ 103.2%
-183.94M▼ 503.5%
-84.87M▲ 53.9%
-223.95M▼ 163.9%
-186.53M▲ 16.7%
-65.27M▲ 0%
Free Cash Flow
41.8M▲ 0%
77.54M▲ 85.5%
95.52M▲ 23.2%
144.32M▲ 51.1%
91.57M▼ 36.6%
82.53M▼ 9.9%
113.55M▲ 37.6%
164.38M▲ 44.8%
131.64M▲ 0%
FCF Margin %
16.75%19.97%17.34%19.36%11.95%11%14.33%20.63%16.71%
FCF Growth %
-85.52%23.19%51.1%-36.55%-9.87%37.59%44.77%39.2%
FCF per Share
0.120.210.350.350.220.200.290.460.39
FCF Conversion (FCF/Net Income)
1.03x1.26x-0.45x-7.08x-4.47x-15.59x11.22x5.52x4.46x
Interest Paid
18.66M48.44M24.52M20.2M30.7M48.8M55.1M40.84M0
Taxes Paid
11.7M19.4M29.23M18.11M4.36M17.24M23.62M13.13M0

GDRX Key Ratios

GoodRx Holdings, Inc. (GDRX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric2019202020212022202320242025TTM
Return on Equity (ROE)
--41.28%-3.27%-3.99%-1.12%2.21%4.54%4.75%
Return on Invested Capital (ROIC)
--983.61%1.94%0.19%-2.57%6.1%10.64%8.98%
Gross Margin
96.39%94.63%93.73%91.51%91.08%93.91%92.77%89.32%
Net Margin
17.01%-53.32%-3.39%-4.28%-1.18%2.07%3.82%3.74%
Debt / Equity
-0.99x0.84x0.88x0.93x0.75x0.10x0.09x
Interest Coverage
2.67x-9.87x0.57x0.32x0.02x1.59x2.33x3.50x
FCF Conversion
1.26x-0.45x-7.08x-4.47x-15.59x11.22x5.52x4.46x
Revenue Growth
55.59%41.85%35.36%2.83%-2.13%5.61%0.57%-1.19%
Related:GDRX Dividend History·GDRX Revenue History·GDRX Price History·GDRX P/E History·GDRX Financial Ratios·GDRX Institutional Holders

GDRX SEC Filings & Documents

GoodRx Holdings, Inc. (GDRX) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 6, 2026·SEC

Material company update

Apr 24, 2026·SEC

Material company update

Apr 3, 2026·SEC

10-K Annual Reports

2
FY 2025

Feb 27, 2025·SEC

FY 2024

Feb 29, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 6, 2026·SEC

FY 2025

Nov 4, 2025·SEC

FY 2025

Aug 6, 2025·SEC

GDRX Frequently Asked Questions

GoodRx Holdings, Inc. (GDRX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

GoodRx Holdings, Inc. (GDRX) reported $787.9M in revenue for fiscal year 2025. This represents a 216% increase from $249.5M in 2018.

GoodRx Holdings, Inc. (GDRX) grew revenue by 0.6% over the past year. Growth has been modest.

Yes, GoodRx Holdings, Inc. (GDRX) is profitable, generating $29.5M in net income for fiscal year 2025 (3.8% net margin).

Dividend & Returns

GoodRx Holdings, Inc. (GDRX) has a return on equity (ROE) of 4.5%. This is below average, suggesting room for improvement.

GoodRx Holdings, Inc. (GDRX) generated $131.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in GDRX back in 2018?

Total return calculator · dividends reinvested · 8+ years of data

See returns →

How much would $100/month in GDRX be worth today?

Dollar cost averaging calculator · DCA vs lump sum

Calculate →